Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$28.3 million.

  • Entrada Therapeutics' Cash from Operations fell 1667.77% to -$28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.9 million, marking a year-over-year decrease of 81596.13%. This contributed to the annual value of -$41.6 million for FY2024, which is 12972.54% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Cash from Operations stood at -$28.3 million, which was down 1667.77% from -$29.5 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Cash from Operations high stood at $203.4 million for Q1 2023, and its period low was -$38.5 million during Q1 2025.
  • Its 4-year average for Cash from Operations is -$6.1 million, with a median of -$25.5 million in 2024.
  • As far as peak fluctuations go, Entrada Therapeutics' Cash from Operations skyrocketed by 106898.19% in 2023, and later crashed by 68756.54% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Cash from Operations (Quarter) stood at -$27.3 million in 2022, then surged by 85.3% to -$4.0 million in 2023, then plummeted by 687.57% to -$31.6 million in 2024, then grew by 10.42% to -$28.3 million in 2025.
  • Its Cash from Operations was -$28.3 million in Q3 2025, compared to -$29.5 million in Q2 2025 and -$38.5 million in Q1 2025.